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Abstract
Background: We have previously reported that RAS-MEK (Cancer Res. 2003 May 1;63(9):2088-95) and TGF-b (Cancer
Res. 2006 Feb 1;66(3):1648-57) signaling negatively regulate coxsackie virus and adenovirus receptor (CAR) cell-
surface expression and adenovirus uptake. In the case of TGF-b, down-regulation of CAR occurred in context of
epithelial-to-mesenchymal transition (EMT), a process associated with transcriptional repression of E-cadherin by, for
instance, the E2 box-binding factors Snail, Slug, SIP1 or ZEB1. While EMT is crucial in embryonic development, it
has been proposed to contribute to the formation of invasive and metastatic carcinomas by reducing cell-cell
contacts and increasing cell migration.
Results: Here, we show that ZEB1 represses CAR expression in both PANC-1 (pancreatic) and MDA-MB-231 (breast)
human cancer cells. We demonstrate that ZEB1 physically associates with at least one of two closely spaced and
conserved E2 boxes within the minimal CAR promoter here defined as genomic region -291 to -1 relative to the
translational start ATG. In agreement with ZEB1’s established role as a negative regulator of the epithelial
phenotype, silencing its expression in MDA-MB-231 cells induced a partial Mesenchymal-to-Epithelial Transition
(MET) characterized by increased levels of E-cadherin and CAR, and decreased expression of fibronectin. Conversely,
knockdown of ZEB1 in PANC-1 cells antagonized both the TGF-b-induced down-regulation of E-cadherin and CAR
and the reduction of adenovirus uptake. Interestingly, even though ZEB1 clearly contributes to the TGF-b-induced
mesenchymal phenotype of PANC-1 cells, TGF-b did not seem to affect ZEB1’s protein levels or subcellular
localization. These findings suggest that TGF-b may inhibit CAR expression by regulating factor(s) that cooperate
with ZEB1 to repress the CAR promoter, rather than by regulating ZEB1 expression levels. In addition to the
negative E2 box-mediated regulation the minimal CAR promoter is positively regulated through conserved ETS and
CRE elements.
Conclusions: This report provides evidence that inhibition of ZEB1 may improve adenovirus uptake of cancer cells
that have undergone EMT and for which ZEB1 is necessary to maintain the mesenchymal phenotype. Targeting of
ZEB1 may reverse some aspects of EMT including the down-regulation of CAR.
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The coxsackie virus and adenovirus receptor (CAR),
encoded by the CXADR gene, is localized at the apico-
lateral/basolateral surface of polarized epithelial cells
and serves as a component of tight junctions, thus parti-
cipating in the sealing of the epithelial layer. In addition
to its basolateral localization, recently, an apically loca-
lized isoform (CAR
Ex8) was described which may be
responsible for initiation of respiratory adenoviral infec-
tions [1]. Furthermore, CAR regulates cardiac conduc-
tance, as demonstrated in a mouse model in which
heart-specific inducible C A Rk n o c k o u tr e s u l t e di n
impaired electrical conductance between atrium and
ventricle [2].
CAR is the primary receptor for adenovirus serotypes 2
and 5 [3] and thus a likely determining factor for the effi-
cacy of adenovirus-based cancer therapy. A number of
mechanisms by which CAR expression is regulated have
been described, but our understanding of how to manip-
ulate CAR expression levels in cancer is incomplete
[4-11]. Learning the molecular machinery regulating CAR
expression could set the stage for pharmacological inter-
ventions aimed at achieving high cell surface CAR levels
to maximize virus uptake.
We previously identified RAS-MEK [5] and TGF-b
signaling [9] as negative regulators of CAR expression in
cancer cell lines. Down-regulation of CAR through
TGF-b occurred in the context of epithelial-to-mesench-
ymal transition (EMT), a process that refers to the for-
mation of mesenchymal cells from epithelial cells
without the involvement ofs t e mc e l l s .D u r i n gE M T ,
both tight junctions at apicolateral surfaces containing
CAR, and more basolateral adherens junctions contain-
ing E-cadherin are disrupted, and cells acquire a motile
phenotype. EMT has evolved as an important develop-
mental program. However, inappropriate activation is
linked to pathological conditions such as fibrosis and
cancer [12]. In the case of cancer, EMT may contribute
to the formation of invasive and metastatic carcinomas
by reducing cell-cell contacts and increasing cell migra-
tion [13-15]. Additionally, the EMT-associated reduction
of cell surface CAR likely makes advanced malignancies
with already poor prognosis less responsive to treatment
with oncolytic adenoviruses [5,9].
One of the most prominent inducers of EMT is TGF-
b. It is postulated that TGF-b inhibits cell cycle progres-
sion, but alters the tumor microenvironment, promotes
EMT, immunosuppression and angiogenesis in advanced
malignancies, thus playing both tumor suppressive and
oncogenic roles during multistage carcinogenesis
[16-22]. The switch from tumor suppressor to oncogene
may occur upon loss of the cytostatic arm of the TGF-b
pathway, for instance through genetic inactivation of
tumor suppressive TGF-b downstream effectors such as
p15INK4b, a cyclin-dependent kinase (CDK) inhibitor
[20].
Mechanisms underlying TGF-b-induced EMT involve
E2 box-binding transcriptional repressors, in particular
Snail (SNAI1), Slug (SNAI2), SIP1 (ZEB2)a n dZ E B 1
(ZEB1). These repressors target genes whose protein
products are instrumental for the integrity of the epithe-
lial phenotype [23-25]. Interestingly, in addition to regu-
lating protein-encoding genes, ZEB1 and SIP1 are both
targets and negative regulators of microRNA-200 (miR-
200) family members. Depending on whether an extra-
cellular stimulus up-regulates ZEB1 or SIP1, or raises
miR-200 levels, the resulting positive feedback loop may
stabilize either a mesenchymal (elevated ZEB1 and/or
SIP1 activity) or an epithelial (increased miR-200 levels)
state [26-28]. Furthermore, consistent with the proposed
contribution of EMT to cancer progression, expression
of E2 box-binding repressors has been observed in sev-
eral malignancies [25,29-32].
The aim of this study was to examine the mechanism
by which TGF-b down-regulates CAR. By investigating
how RAS-MEK [5] and TGF-b signaling [9] impact on
CAR expression, we noticed similar expression patterns
for CAR and E-cadherin, suggesting common underlying
regulatory mechanisms. We show here that for the regu-
lation through TGF-b this is indeed the case. Both CAR
and E-cadherin promoters are structurally conserved
around two closely spaced E2 boxes. We provide evi-
dence that ZEB1, which has previously been reported to
repress E-cadherin expression [25,33-36], also down-reg-
ulates CAR. This study, in combination with the work
of others [26,27,34,36], identifies ZEB1 as a potential
therapeutic target for strategies aimed at improving
uptake of therapeutic adenoviruses and preventing or
reversing cancer-associated EMT processes while leaving
the tumor suppressive functions of TGF-b unaffected.
As our work was in progress, a report was published
demonstrating that TGF-b may repress the mouse CAR
promoter through Snail in combination with Smad3/4
[37]. Our data is consistent with a model in which both
ZEB1 and Snail-Smad3/4 can simultaneously repress the
human CAR promoter.
Methods
Additional methods and further details including antibo-
dies are provided in the Additional file 1.
In silico analyses
Orthologous CAR upstream sequences were exported
from the GenBank (http://www.ncbi.nlm.nih.gov) or
Ensemble (http://www.ensembl.org) database according
to the positions of the predicted translational start ATG
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Page 2 of 16(Additional file 1, Table S1). The sequence alignment
was performed with CLUSTAL W 1.83 [38] with sub-
sequences (-25 to +60 relative to the “C“ of the
CACCTG E2 box corresponding to E2 box 1 in
Figure 1A and 1B) encoded within the -291/-1 region of
the human CXADR (CAR) gene. Conserved nucleotides
of the aligned sequences were shaded with BOXSHADE
3.21 (http://www.ch.embnet.org/software/BOX_form.
html). A stretch of dog CAR sequence previously not
available in public databases was sequenced at
the University of California, San Francisco (UCSF)
Helen Diller Family Comprehensive Cancer Center
(HDFCCC) Genome Core (San Francisco, CA, USA)
using PCR-amplified genomic DNA extracted from
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Figure 1 Structure of the CAR promoter. A. Several CXADR (CAR) upstream fragments were PCR-amplified from human genomic DNA and
cloned into a firefly (FF) luciferase vector in endogenous constellation, i.e. without vector sequence between the CAR regulatory region, 5’-UTR
and the translational start of the luciferase coding sequence. The resulting 5’-deletion series was transfected into PANC-1, MDA-MB-231 and
H460 cells, in combination with pRL-SV40 (Promega) encoding renilla (RL) luciferase. Cells were lysed twenty-four hours post transfection, and
promoter activities were measured with the Dual-Luciferase
® Reporter Assay System (Promega). Reporter activities are displayed as fold changes
of the FF:RL luciferase RLU (relative light unit) ratios relative to the empty vector. B. Alignment of orthologous CAR promoter sequences and
identification of conserved putative ETS and CRE sites [40-42,49]. A region in which mouse CAR transcripts are likely initiated is indicated (TSS)
[56]. Human CAR transcripts may start at around 150 bp upstream of the translational start ATG [10]. C. Wild-type (WT), ETS and CRE mutant
-291/-1 CAR promoter constructs were transfected into PANC-1 and MDA-MB-231 cells. Cell lysis and measurements of promoter activities were
conducted as in A. Error bars represent standard deviations (biological triplicates). p < 0.001 (***), p < 0.01 (**) (Student’s t-test: 1-tailed, equal
variance).
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sequence was submitted to the GenBank database
(NCBI, accession number EU744539). In Figure 1B
highlighted ETS and cAMP responsive element (CRE)
elements are represented by or are highly similar to
TRANSFAC
® [40] consensus sequences [ETS:T R A N S -
FAC
® acc. # R02153 (ETS1$CONS, SMGGAWGY),
CRE:T R A N S F A C
® acc. # R04110 (CREB$CONS_01,
T G A C G T M W ) ,S=Go rC ,W=Ao rT ,M=Ao rC ,
Y = C or T] and motifs in published reports (CRE,
[41,42]).
Cell lines
The human pancreatic cancer cell line PANC-1 [9], and
the human breast cancer cell line MDA-MB-231 (gift
from Dr. J. Gray, Lawrence Berkeley National Labora-
tory) were maintained in Dulbecco’s Modified Eagle
Medium (DMEM; UCSF Cell Culture Facility, San Fran-
cisco, CA, USA) supplemented with 10% Fetal Bovine
Serum (FBS; Valley Biomedical, Inc.; Winchester, VA,
USA) and 100 units/mL penicillin “G”, 100 mcg/mL
streptomycin SO4 (both UCSF Cell Culture Facility),
and 5 microgram/mL Plasmocin™ (InvivoGen, San
Diego, CA, USA). The human non-small cell lung can-
cer cell line H460 (gift from Dr. D. Jablons, UCSF) [43]
was grown in RPMI-1640 (Gibco/Invitrogen, Carlsbad,
CA, USA), supplemented with 10% FBS, penicillin,
streptomycin and Plasmocin (all supplemented compo-
nents as above).
Constructs
Various CAR [promoter]-[5’-UTR] fragments were inde-
pendently PCR-amplified from human genomic DNA
and cloned into pGL3Ba-DESneo3N. The sequence
between the translational ATG start codons of CAR and
luciferase was removed by restriction digestion, followed
by ethanol precipitation and re-ligation. Mutations at
the E2 boxes, ETS and CRE motifs were introduced into
the -291/-1 luciferase construct. Inducible Myc-tagged
ZEB1 expression constructs were generated by replacing
the mSIP1 coding sequence (cds) of pUHD10.3SIP1 [39]
through PCR-amplified human ZEB1 cds. Primer
sequences and cloning strategies are provided as supple-
mental information (Additional file 1).
Immunofluorescence and F-actin staining
PANC-1 and MDA-MB-231 cells were grown on Lab-
Tek™ Chamber Slides (Nalge Nunc/Thermo Fisher
Scientific, Inc., Rockford, IL, USA) and treated with 5
ng/mL platelet-derived human TGF-b1 (R&D Systems,
Minneapolis, MN, USA) for four days. For E-cadherin
staining, cells were fixed with a 1:1 solution of methanol
and acetone at -20°C, and unspecific epitopes were
blocked with 3% bovine serum albumin (BSA) (Sigma-
A l d r i c h ,S t .L o u i s ,M O ,U S A). Then, cells were incu-
bated for 1 hour with 2 microgram/mL of the mouse
anti-E-cadherin antibody (clone HECD-1, Invitrogen).
For F-actin and vimentin stainings, cells were fixed for
15 min. with IC Fixation Buffer (Invitrogen) and per-
meabilized for 5 min. with 0.1% Triton X-100 (Aqua
Solutions, Deer Park, TX, USA). Then, unspecific epi-
topes were blocked with 3% BSA and cells were incu-
bated for 1 hour with a 1:100 dilution of phalloidin
conjugated to Texas Red
® (Invitrogen) or with a 1:100
dilution of the rabbit anti-vimentin antibody (D21H3,
Cell Signaling Technology, Inc., Danvers, MA, USA).
For E-cadherin and vimentin stainings secondary antibo-
dies conjugated to Alexa Fluor
® 488 (Molecular Probes/
Invitrogen) were used. Nuclei were stained with DAPI,
and samples mounted onto glass slides using Vecta-
shield (Vector Lab, Burlingame, CA, USA). Immuno-
fluorescence images were obtained using a Zeiss Imager
Z2 microscope (Carl Zeiss, Jena, Germany) equipped
with an AxioCam camera and processed with Axiovision
software. Digital images were adjusted for contrast and
brightness using Adobe Photoshop CS5.
RNA interference
PANC-1 cells were pre-treated for two days with 5 ng/
mL platelet-derived human TGF-b1 (R&D Systems),
then, and two days later, siRNA-transfected by using
Lipofectamine RNAiMax (Invitrogen). TGF-b treatment
was continued through the first, until two days after the
second transfection. MDA-MB-231 cells were similarly
transfected, but not stimulated with ectopic TGF-b.C e l l
lysis for protein harvest, flow cytometric analysis of cell-
surface CAR and adenovirus infections were carried out
four days after the initial transfection. Abbreviations:
UT, untransfected; Ctrl #1, siControl ON-TARGETplus
Non-targeting siRNA #1 (Dharmacon/Thermo Fisher
Scientific, Inc.); Ctrl #2, firefly luciferase-targeting
siRNA; ZEB1 siRNA #1/#2, ZEB1-targeting siRNAs. Ctrl
#2 and ZEB1 siRNA sequences are provided in Addi-
tional file 1 (Table S3) and were obtained by using the
siDESIGN
® Center (Dharmacon/Thermo Fisher Scienti-
fic, Inc.). Detailed information is provided as supple-
mental information (Additional file 1).
Expression analysis by real-time RT-PCR
Total RNA was extracted with the RNeasy kit (Qiagen,
Valencia, CA, USA). Reverse-transcription and real-time
PCR were carried out at the UCSF HDFCCC Genome
Core with the primer/probe sequences listed in Addi-
tional file 1 (Table S3) and with Expression Assays
(Applied Biosystems, Foster City, CA, USA) for CDH1
(E-cadherin, Hs00170423_m1), ZEB1 (Hs00611018_m1 or
Hs00232783_m1), ZEB2 (SIP1, Hs00207691_m1), SNAI1
(Snail, Hs00195591_m1), SNAI2 (Slug, Hs00161904_m1)
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lyzed by relative quantitation [44].
Immunoblotting and cell fractionation
Antibodies used include rabbit anti-phospho-Smad2
(Ser465/467, Cell Signaling Technology, Inc.), goat anti-
ZEB1 (E-20, Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA), mouse anti-b-tubulin (Sigma-Aldrich),
mouse anti-PARP (clone C2-10, Pharmingen/BD Bios-
ciences, San Jose, CA, USA), mouse anti-GAPDH-Perox-
idase Conjugate (Sigma-Aldrich), and mouse anti-Myc
Tag (clone 4A6; Upstate/Millipore, Charlottesville, VA,
USA). Cell fractionation was carried out via the NE-
PER
® Nuclear and Cytoplasmic Extraction Reagents kit
(Pierce/Thermo Fisher Scientific, Inc.). A description of
the Western blot procedure and further antibody refer-
ences are provided elsewhere [9].
Luciferase reporter assays
All transfections involving CAR promoter constructs
were carried out by using FuGENE HD (Roche, India-
napolis, IN, USA) (3 microliter per 1 microgram of
DNA), and included co-transfection of the renilla luci-
ferase-encoding pRL-SV40 plasmid (Promega, Madison,
WI, USA) for normalization. Cells were subconfluent
at the time of transfection. For the identification of the
CAR promoter, cells were grown in 24-well plates and
transfected with 750 nanogram of the pGL3Ba-DES-
neo3N reporter plasmids in combination with 10 nano-
gram pRL-SV40. To transfect equimolar amounts of
each CAR promoter construct of the CAR upstream 5’-
deletion series, plasmid size differences were compen-
sated by co-transfection with the pGL3Ba-DESneo3N-
EmVec empty vector plasmid. For the characterization
of the ETS and CRE elements, cells were grown in 6-
well plates and transfected with 3 microgram of wild-
type, ETS or CRE element-mutated -291/-1 luciferase
construct in combination with 50 nanogram pRL-SV40.
For the characterization of the E2 boxes as binding
sites for ZEB1, cells were grown in 24-well plates and
transfected with 500 nanogram of wild-type and E2
box-mutated -291/-1 luciferase construct, 125 nano-
gram pRevTet-Off (Clontech Laboratories, Inc./Takara
Bio, Inc., Otsu, Shiga, Japan), and 375 nanogram
pTRE-6Myc-deltaATG-hZEB1 in combination with 10
nanogram pRL-SV40. 4-6 hours post transfection, the
transfection medium was removed, and around 1.5-2
hours later, stimulation with 2 microgram/mL doxycy-
line hyclate (Sigma-Aldrich) was begun. Cells were
lysed twenty-four (to define the minimal CAR promo-
ter and to characterize ETS and CRE elements) or
forty-eight (to assess effects of Myc-ZEB1 on the WT
and mutant CAR promoter) hours post transfection
with Passive Lysis Buffer (Promega). Reporter activities
were measured with the Dual-Luciferase
® Reporter
Assay System (Promega).
Biotinylated Oligonucleotide Precipitation Assay
One day after seeding 3 × 10
6 PANC-1 cells per 10 cm-
dish, cells were transiently co-transfected with pRevTet-
Off (4.0 microgram) (Clontech Laboratories, Inc./Takara
Bio, Inc.) in combination with pTRE-6Myc-deltaATG-
hZEB1 (12.0 microgram) by using FuGENE HD (Roche)
(3 microliter per 1 microgram of DNA). Control lysates
were made from PANC-1 cells seeded at a density of 5
×1 0
5 cells per well (6-well plate) and transfected with
the same plasmids. Four hours post transfection, trans-
fection medium was replaced by antibiotic-containing
full medium. Six hours post transfection, medium was
again replaced by full medium with (to repress ZEB1) or
without (to induce ZEB1) 2 microgram/mL doxycycline
hyclate (Sigma-Aldrich). Forty-eight hours after transfec-
tion, oligonucleotide precipitations were carried out fol-
lowing a modified version of the procedure described by
others [39,45]. ZEB1 was detected with the mouse
monoclonal anti-Myc Tag clone 4A6 (Upstate/Millipore)
antibody at 1 microgram/mL. Detailed information is
provided as supplemental information (Additional file 1).
Chromatin Immunoprecipitation
PANC-1 cells were transiently transfected with pTRE-
6Myc-deltaATG-hZEB1 in combination with pRevTet-
Off (Clontech) using FuGENE HD (Roche). For the con-
trol sample, six hours after addition of the plasmid
DNA to the cells, expression of Myc-ZEB1 was sup-
pressed with 2 microgram/mL doxycyline hyclate
(Sigma-Aldrich). The next day, cells of both control and
experimental samples were stimulated with 5 ng/mL
platelet-derived human TGF-b1 (R&D Systems). Forty-
eight hours after transfection, chromatin was cross-
linked with paraformaldehyde and subjected to Chroma-
tin Immunoprecipitation (ChIP) at the University of
California at Davis (UC Davis) Genome Center (CA,
USA), following a protocol developed by the Farnham
laboratory (UC Davis, Davis, CA, USA) (http://www.gen-
omecenter.ucdavis.edu/farnham/pdf/FarnhamLabChIP%
20Protocol.pdf). In short, samples were sonicated using
a BioRuptor™ Sonicator (Diagenode, Inc.; Sparta, NJ,
USA), DNA was precipitated with an anti-Myc Tag anti-
body (clone 4A6; Upstate/Millipore), and SYBR Green I
real-time PCR with the precipitated DNA as template
was conducted using the iQ™ SYBR
® Green Supermix
(Bio-Rad Laboratories, Hercules, CA, USA) using CAR
promoter-specific primers (Additional file 1, Table S3).
Adenovirus infections
Following a four-day siRNA treatment period, PANC-1
cells were infected with 300 microliter/well (12-well
Lacher et al. Molecular Cancer 2011, 10:91
http://www.molecular-cancer.com/content/10/1/91
Page 5 of 16plates) Ad-GFP [9] diluted in DMEM (UCSF Cell Cul-
ture Facility) supplemented with 2% FBS (Valley Bio-
medical, Inc.) at a Multiplicity Of Infection (MOI) of
200. Ninety minutes post-infection, virus was replaced
by regular growth medium. Twenty-four hours post-
infection, Ad-GFP uptake was analyzed by both flow
cytometry (GFP intensities) and real-time PCR (virus
copy numbers). For the latter approach genomic/ade-
noviral DNA was first extracted with the DNeasy
®
Blood & Tissue kit (Qiagen) and then subjected to
ethanol precipitation to potentially improve DNA qual-
ity. Relative virus copy numbers were determined at
the UCSF HDFCCC Genome Core by TaqMan PCR
amplification of the adenovirus fiber gene (primer/
probe sequences shown in Additional file 1, Table S3)
normalized to genomic DNA amplified with a pool of
primers for D1S2868, D2S385, D4S1605, D5S643,
D10S586, and D11S1315 [46]. Data were analyzed by
relative quantitation [44].
Flow cytometry
Live cells were stained with an anti-CAR-phycoerythrin
(PE) antibody (E1-1, mouse monoclonal; Santa Cruz
Biotechnology, Inc.) or PE-conjugated control IgG-PE
(mouse monoclonal IgG1 , Pharmingen/BD Bios-
ciences) while rotating for 60 minutes at 4°C. Cells were
then washed and resuspended in 1 micromolar TO-
PRO
®-3 iodide (TP3, for exclusion of dead cells) (Invi-
trogen) in PBS supplemented with 5% FBS, and analyzed
by flow cytometry using FACSCalibur (BD Biosciences)
or Accuri C6 (Accuri Cytometers, Inc., Ann Arbor, MI,
USA/BD, Franklin Lakes, NJ, USA) flow cytometers.
Cell-surface CAR was detected in the FL2 channel, non-
viable cells, stained by TP3 and detected in the FL4
channel, were excluded. For the analysis of live Ad-GFP
infected cells, GFP was detected in the FL1 channel.
TP3-positive cells were excluded. Data analysis was car-
ried out with Cyflogic™ software (CyFlo Ltd, Turku,
Finland). Detailed information is provided as supple-
mental information (Additional file 1).
Results
Defining the CAR promoter
TGF-b down-regulates CAR mRNA and protein levels
[9]. Since neither mRNA nor protein stability appeared
to be affected by TGF-b [9], regulation of CAR expres-
sion likely occurs at the promoter level. Bowles et al.
reported that the locus of the functional human CAR
gene (CXADR) is on chromosome 21, 21q11.2 [47].
However, even though 21q11 harbors CAR sequence,
this locus encodes a CAR pseudogene lacking introns.
The functional human CAR gene is located on 21q21.1
(Entrez Gene, Gene ID: 1525, NCBI).
To experimentally determine the CAR promoter
region we cloned several fragments of CAR upstream
sequence as a 5’-deletion series into pGL3Ba-DESneo3N
(a luciferase reporter vector we engineered allowing
recombination-based cloning of [promoter]-5’-UTR frag-
ments in endogenous constellation, i.e. without vector
sequence between the regulatory fragments and the luci-
ferase coding sequence (Figure 1A). To identify genomic
regions involved in the regulation of CAR expression,
we transfected the 5’-deletion series into PANC-1
(human pancreatic cancer), H460 (human non-small cell
lung cancer), and MDA-MB-231 (human breast cancer)
cells. In all cell lines, reporter activities were higher for
the genomic fragments -2017/-1, -1195/-1, -681/-1,
-291/-1 than for -926/-1, and -890/-1 (Figure 1A). This
may suggest that silencer elements are present between
-1194 and -682, and that positive regulatory elements
further upstream override this negative regulation. In all
cell lines, maximal promoter activity was measured with
the -291/-1 construct, whereas the -96/-1 fragment was
only minimally active. Therefore, the CAR core promo-
ter, which interacts with the DNA polymerase II com-
plex, and the adjacent proximal promoter [48], are
located within -291 and -1 relative to the translational
s t a r tA T G .T h i si si na g r e e m e n tw i t hap r e v i o u sr e p o r t
by Pong et al. illustrating that CAR transcription is
likely initiated at around -150 relative to the ATG [10].
Since each promoter/5’-UTR fragment was individu-
ally PCR-amplified we were able to identify a single
nucleotide polymorphism (SNP) at position -579, with
the base being either thymine (in the -2017/-1, -1195/-1,
-926/-1 fragments) or cytosine (-890/-1 and -681/-1
fragments). It is unlikely that this SNP influences CAR
expression, since the reporter activities of the -926/-1
and the -890/-1 fragments, which differ only in 36 bp,
are very similar, despite the polymorphic difference (Fig-
ure 1A and data not shown).
By aligning CAR upstream sequences from diverse
species ranging from zebrafish to man, several con-
served elements were recognized within the -291/-1
fragment: putative binding sites for ETS transcription
factors and for c-AMP responsive element (CRE)b i n d -
ing protein (CREB) [41,42,49], as well as two closely
spaced E2 boxes (Figure 1B). The latter elements are
particularly interesting since they are located in a simi-
lar genetic context than the E2 boxes in the human E-
cadherin promoter to which E2 box-binding repressors
such as SIP1 [23,33,35,39] and ZEB1 [25,33-36] bind.
To investigate whether the ETS and CRE elements are
biologically relevant, we transiently transfected PANC-
1 and MDA-MB-231 cells with ETS or CRE mutant
-291/-1 luciferase constructs. Inactivation of either
motif reduced CAR promoter activity, suggesting that
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sion (Figure 1C).
Down-regulation of CAR in TGF-b-induced EMT
The presence of the dual E2 box motif in the CAR pro-
moter suggests that SIP1 and/or ZEB1 repress(es) CAR
expression upon TGF-b treatment in cells undergoing
EMT. If true, SIP1 and/or ZEB1 expression may be sti-
mulated by TGF-b. We chose PANC-1 cells as an EMT
model in this study as these cells are known to undergo
TGF-b-induced EMT [9,50]. In agreement, untreated
cells stained positive for cells u r f a c eE - c a d h e r i nb u tn o t
for vimentin intermediate filaments or F-actin, thus
demonstrating epithelial characteristics (Figure 2). Con-
versely, TGF-b i n d u c e da nE M Tp r o c e s si nP A N C - 1
cells as shown by lack of E-cadherin staining. In con-
trast, MDA-MB-231 cells did not express cell surface E-
cadherin, but strongly stained positive for vimentin fila-
ments or F-actin, thus demonstrating mesenchymal fea-
tures (Figure 2). To address whether SIP1 and/or ZEB1
may affect CAR expression upon TGF-b stimulation, we
measured their mRNA levels in PANC-1 and MDA-
MB-231 cells. In agreement with the data obtained by
immunofluorescence (Figure 2), MDA-MB-231 cells
demonstrated mesenchymal features (lack of E-cadherin
expression and high SIP1 and ZEB1 levels) (Figure 3B-
D). It is of note that the cells used in this study are
morphologically markedly different and may proliferate
faster than MDA-MB-231 cells from the American Type
Culture Collection (ATCC, Manassas, VA), and likely
represent a derivative of the cell line. In agreement with
our previous report, in PANC-1 cells, both CAR and E-
cadherin mRNA levels were reduced as consequence of
TGF-b treatment (Figure 3A and 3B) [9], while ZEB1
expression was modestly stimulated (Figure 3D). Despite
the presence of a dual E2 box sequence in the CAR pro-
moter single E2 box-binding repressors, such as Snail
and Slug, may regulate CAR expression upon TGF-b sti-
mulation. Indeed, PANC-1 cells responded to TGF-b
stimulation with increased Snail expression (Figure 3E).
This data is consistent with a recent report demonstrat-
ing that Snail-Smad3/4 is a physiological regulator of
Figure 2 Effect of TGF-b on EMT markers. MDA-MB-231 and PANC-1 cells were stimulated with TGF-b for four days, then assessed for
E-cadherin and vimentin expression/localization by immunofluorescence, or were stained with phalloidin conjugated to Texas Red
® to visualize
F-actin. Cell surface expression of E-cadherin is a hallmark of an epithelial phenotype. Vimentin intermediate filaments and F-actin are features of
mesenchymal cells.
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Page 7 of 16CAR in murine cells [37]. In addition to Snail, also Slug
mRNA levels increased in PANC-1 cells following addi-
tion of TGF-b. However, as they remained low, Slug is
not likely a regulator of CAR in these cells. Interestingly,
despite their mesenchymal features, MDA-MB-231 cells
expressed relatively high CAR levels (Figure 3A), and,
similarly to PANC-1 cells, also down-regulated CAR
upon TGF-b treatment. However, in MDA-MB-231
cells, TGF-b stimulated Slug expression, suggesting that
in this cell line Slug potentially inhibits CAR expression
(Figure 3F).
E2 box-dependent repression of the human CAR
promoter by ectopic ZEB1
A recent study indicates that CAR may be transcription-
ally repressed by Snail-Smad3/4 in TGF-b stimulated
murine epithelial cells [37]. However, microarray data
suggests that siRNA-mediated knockdown of ZEB1 in
human MDA-MB-231 cells may increase CAR mRNA
levels [34]. Given the above described orthologously
conserved nature of the E2 boxes in the CAR promoter,
we hypothesized that the suggested repression of CAR is
mediated by ZEB1 by directly repressing the CAR pro-
moter at the E2 boxes, and is not an indirect conse-
quence of the MET induced by the knockdown of
ZEB1. To test this hypothesis, we co-transfected PANC-
1 cells with an inducible Myc-tagged human ZEB1
expression plasmid, in combination with wild-type or E2
box-mutant CAR promoter reporter constructs. Induc-
tion of ZEB1 was performed in the context of a “Tet-
OFF” system, in which the presence of doxycycline
repressed ZEB1 expression, and carried out as a “dual
luciferase” approach in which firefly (FF) luciferase was
driven off the CAR promoter, and renilla (RL) luciferase
was expressed through an SV40 promoter. While induc-
tion of ZEB1 repressed the wild-type CAR promoter, it
also repressed the single E2 box-mutant promoters
(Bx1, Bx2), although to a lesser degree. Repression of
the CAR promoter was further reduced when both E2
boxes (Bx1+2) were inactivated. Importantly, compared
to the wild-type promoter, all mutations resulted in sig-
nificantly (p < 0.05) higher relative promoter activities
i nt h ep r e s e n c eo fZ E B 1s u g g e s t i n gt h a tZ E B 1i n d e e d
represses the CAR promoter E2 box-dependently (Figure
4A). It is important to note that a determination of the
exact percentage of repression appeared not possible
with the chosen dual luciferase approach, as various
CAR promoter-independent factors affected the expres-
sion of both FF and RL luciferase. However, when cor-
recting for such parameters mathematically (data not
shown), several types of adjustment revealed stronger
repression of the wild-type compared to the dual E2
box-mutant (Bx1+2) CAR promoter.
The presence of the dual E2 box motif suggests that,
in addition to ZEB1, also SIP1 may repress the CAR
promoter. Indeed, overexpression of Myc-tagged SIP1
[39] repressed CAR promoter activity E2 box-depen-
dently (data not shown). However, since TGF-b neither
increased SIP1 mRNA expression, nor are the SIP1
mRNA levels high in PANC-1 cells (Figure 3C) SIP1 is
unlikely the main regulator of CAR in TGF-b-mediated
EMT in our PANC-1 system.
ZEB1 binds to the CAR promoter
To determine whether ZEB1 indeed physically binds to
the E2 boxes in the CAR promoter, we overexpressed
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Figure 3 E2 box-binding repressor expression upon TGF-b
stimulation. PANC-1 and MDA-MB-231 cells were treated with
recombinant human TGF-b1 for four days. mRNA expression of
CXADR (CAR) (A), CDH1 (E-cadherin) (B), ZEB2 (SIP1) (C), ZEB1 (D),
SNAI1 (Snail) (E), and SNAI2 (Slug) (F) was measured by TaqMan real-
time PCR. Expression data were normalized to H3F3A (H3 histone,
family 3A) mRNA levels (arbitrary units). A-F. Error bars represent
standard deviations (biological triplicates). p < 0.001 (***), p < 0.01
(**), p < 0.05 (*) (Student’s t-test: 1-tailed, equal variance). Absence
of * indicates p ≥ 0.05, or decrease of E2 box-binding repressor
expression upon TGF-b stimulation.
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Page 8 of 16Myc-tagged human ZEB1 in PANC-1 cells and incu-
bated the cell extracts with biotinylated oligonucleotides
composed of a region of the CAR promoter containing
the two E2 boxes (Additional file 1, Table S3). A similar
strategy was used to elegantly demonstrate binding of
SIP1 to the E-cadherin promoter [39]. Following pull-
down with streptavidin-conjugated agarose resin, Myc-
ZEB1 was detected by conventional Western blotting
with an anti-Myc tag antibody. A strong signal was
obtained with the oligonucleotides representing both
wild-type and E2 box 2-mutant CAR promoter
sequence. A mutation in either only E2 box 1 or in both
E2 boxes prevented binding of ZEB1 to the oligonucleo-
tides (Figure 4B). We conducted the same assay with
Myc-tagged SIP1 [39] and, interestingly, observed a
similar binding pattern (data not shown). However, as
outlined above, SIP1 is unlikely the main repressor of
CAR in TGF-b-mediated EMT in PANC-1 cells. Taken
together, our data indicate that ZEB1 interacts with E2
box 1 but not with E2 box 2 (see Figure 1A for the loca-
tion of E2 box 1 and 2 within the CAR promoter). It is
conceivable that ZEB1 might still require both E2 boxes
in the CAR promoter for binding, but the point muta-
tion in E2 box 2 was insufficient to prevent binding
(Figure 4C).
To ascertain whether ZEB1 also binds to the chromo-
somal CAR promoter in PANC-1 cells stimulated with
TGF-b, a Chromatin Immunoprecipitation (ChIP) assay
was conducted with cells transiently transfected with
inducible Myc-ZEB1. As demonstrated in Figure 4D,
precipitation of CAR DNA with an anti-Myc Tag anti-
body was apparent when Myc-ZEB1 was induced, sug-
gesting binding of ZEB1 to genomic CAR promoter
sequence. Nevertheless, some binding was also observed
when Myc-ZEB1 was repressed (Figure 4D). However,
this latter effect is likely due to leakiness of the system
allowing some Myc-ZEB1 expression even in the pre-
sence of the repressor (doxycycline) (Figure 4E and
Additional file 1, Fig. S1). As determined from sample
aliquots removed prior to crosslinking, total ZEB1
mRNA levels were approximately 30 fold higher in the
ChIP experiment following induction of Myc-ZEB1
expression by absence of doxycycline (Figure 4E).
ZEB1 represses CAR in mesenchymal cells
We sought to investigate whether ZEB1 also contributes
to the repression of CAR in PANC-1 cells in the context
of TGF-b-mediated EMT, and whether it mediates CAR
repression in established mesenchymal MDA-MB-231
cells. TGF-b reduces both CAR and E-cadherin protein
levels in the absence but not in the presence of ZEB1
siRNA suggesting that the TGF-b-induced repression of
either protein requires ZEB1 (Figure 5A). Similarly,
ZEB1 plays a pivotal role in maintaining mesenchymal
characteristics of MDA-MB-231 cells, since siRNA-
mediated knockdown of ZEB1 induces a partial MET,
illustrated by the up-regulation of epithelial markers
such as CAR and E-cadherin, or the down-regulation of
the mesenchymal marker fibronectin (Figure 5A and
[34]). Interestingly, even though both siRNAs reduced
ZEB1 protein levels similarly, transfection of PANC-1
cells with siRNA #2 down-regulated phospho-Smad2
(Figure 5A). Since ZEB1 siRNA #2 has a seed region
that is 100% complementary to a region within the
3’UTR of phosphoinositide-3-kinase, regulatory subunit
1 (alpha) (PIK3R1, Entrez Gene, Gene ID: 5295, NCBI)
[51], the effect on Smad2 might have been a conse-
quence of reduced PI3K activity. The requirement of
PI3K signaling for TGF-b1-mediated C-terminal phos-
phorylation of Smad2 was previously demonstrated in
NMuMG cells [52].
TGF-b does not affect ZEB1 protein levels or subcellular
localization
While TGF-b only minimally up-regulated ZEB1 mRNA
in PANC-1 cells (Figure 3D and Additional file 1, Fig.
S1), effects at the protein level varied: some (Figure 5A)
b u tn o ta l l( F i g u r e5 B )e x p e r i m e n t ss u g g e s t e dt h a ts t i -
mulation by TGF-b increases the total ZEB1 protein
levels. To address this question systematically, we mea-
sured ZEB1 protein levels over time, with harvests of
the total protein fractions in twenty-four hour intervals.
Indeed, while CAR was down-regulated at every time
point in the TGF-b-treated samples, ZEB1 levels
remained unchanged throughout the time-course (Fig-
u r e5 B ) .T oi n v e s t i g a t ew h e t h e rT G F - b promotes
nuclear entry of ZEB1 as a mechanism to increase the
latter protein’s activity as a transcriptional repressor of
CAR, we measured ZEB1 protein levels in both nuclear
and cytoplasmic fractions. Interestingly, ZEB1 appears
to be exclusively localized in the nucleus, both in the
presence and absence of TGF-b. In agreement with the
total ZEB1 protein data, TGF-b stimulation for forty-
eight hours did not increase the nuclear ZEB1 levels
(Figure 5C).
ZEB1 is necessary for TGF-b-induced EMT in PANC-1 cells
As demonstrated above, ZEB1 total, nuclear and cyto-
plasmic protein levels were little affected by TGF-b,
whereas knockdown experiments suggested that ZEB1
is a critical component of the TGF-b-induced EMT
process in PANC-1 cells (Figure 5A-B). To address this
dilemma, we tested the hypothesis that TGF-b can
activate ZEB1 rather than increase its protein levels.
However, in reporter assays carried out with PANC-1
cells, TGF-b did not appear to enhance the repressor
effect of overexpressed ZEB1 on the CAR promoter
(data not shown). Still, even though this data does
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Figure 4 E2 box-dependent repression of the CAR promoter and binding of ZEB1 to CAR promoter oligonucleotides and chromatin. A.
PANC-1 cells were transfected with CAR promoter/firefly (FF) luciferase constructs (-291/-1) in combination with pRL-SV40 (Promega) encoding
renilla (RL) luciferase, an inducible Myc-ZEB1 expression construct, and a “Tet-OFF” plasmid allowing induction of ZEB1 by absence (-Dox), and
repression by addition (+Dox) of doxycycline to the culture medium. Cells were lysed forty-eight hours post transfection, and promoter activities
were measured with the Dual-Luciferase
® Reporter Assay System (Promega). Reporter activities are displayed as fold changes of the FF:RL
luciferase RLU ratios relative to the empty vector. Error bars represent standard deviations (biological duplicates). B. In PANC-1 cells ectopically
expressed Myc-tagged ZEB1 was precipitated with streptavidin-agarose resin and biotinlyated E-cadherin or CAR promoter oligonucleotides, and
then subjected to immunoblotting and detection with an anti-Myc tag antibody. C. Mutations at the E2 boxes in the constructs transfected in A,
and in the oligonucleotides used to precipitate ZEB1 (B). E-cadherin promoter mutations are described [39]. D. ChIP assay conducted with PANC-
1 cells transiently transfeced with Myc-ZEB1 and stimulated with TGF-b. Myc-ZEB1 was precipitated with an anti-Myc Tag antibody. Co-
precipitated DNA was amplified with CAR promoter-specific primers flanking E2 boxes 1 and 2. Shown are SYBR Green I real-time PCR data,
normalized to input DNA (prior to precipitation with anti-Myc Tag antibody or control IgG). E. SYBR Green real-time PCR demonstrating
overexpression of the total ZEB1 levels in the experiment shown in D. Abbreviations: TCL, total cell lysate; Dox, doxycyline; WT, wild-type; Bx 1,
E2 box 1; Bx 2, E2 box 2; Bx 1+2, E2 boxes 1+2; Bx1+3, E2 boxes 1+3 ([39]). p < 0.001 (***), p < 0.01 (**), p < 0.05 (*), n.s.: not significant
(Student’s t-test: 1-tailed, equal variance).
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Page 10 of 16not support our hypothesis, the real effect of TGF-b
on ZEB1 may have been masked as ZEB1 was likely
highly overexpressed (Additional file 1, Fig. S1). Alter-
natively, our data is consistent with a model in which
ZEB1 constitutively binds to one of the two E2 boxes
(E2 box 1, Figure 4B) in the CAR promoter thereby
controlling the basal levels of CAR. TGF-b may further
repress the CAR promoter via the second E2 box (E2
box 2), for instance by activating Snail-Smad3/4 [37]
(Figure 6).
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Page 11 of 16ZEB1 knockdown facilitates adenovirus uptake
An increase in CAR expression following ZEB1 knock-
down may improve therapies with oncolytic adeno-
viruses if it translates into elevated cell-surface CAR
levels [3]. We addressed this question in both PANC-1
EMT, and MDA-MB-231 MET models. In the former
system, we employed the strategy outlined above,
i.e. knockdown of ZEB1 in combination with TGF-b
treatment. Consistent with the Western blot data
(Figure 5A), ZEB1 knockdown indeed antagonized the
TGF-b-induced reduction of the cell-surface CAR levels
measured by flow cytometry (Figure 7A). Analogously,
silencing of ZEB1 in MDA-MB-231 cells increased cell
surface CAR expression (Figure 7B).
In agreement with the total CAR protein (Figure 5A)
and cell-surface CAR (Figure 7A) data, PANC-1 cells
with silenced ZEB1 expression were more susceptible to
infection with a green fluorescence protein (GFP)-
encoding adenovirus (Ad-GFP) [9] than the TGF-b trea-
ted non-silencing controls. This effect was apparent
both at the level of GFP signal intensity (Figure 7C) and
virus copy number (Figure 7D). For both methods, cells
were harvested twenty-four hours post infection and
were either analyzed by flow cytometry (GFP signal) or
by TaqMan PCR (copy number) using adenoviral DNA
(extracted together with cellular genomic DNA) as tem-
plate. This data indicates that knockdown of ZEB1
might be a suitable approach to improve cellular uptake
of therapeutic adenoviruses.
Discussion
Up-regulation of CAR may be achieved by treatment
with pharmacological inhibitors of RAS-MEK [5], of
TGF-b signaling [9], or with HDAC inhibitors [6,7].
H e r e ,w eh a v ed e m o n s t r a t e dt h a tZ E B 1p l a y sap r o m i -
nent role in the TGF-b-induced down-regulation of
CAR, and that knockdown of ZEB1 is sufficient to
improve adenovirus uptake.
We have previously noticed similar expression pat-
terns for CAR and E-cadherin, and thus hypothesized
that the underlying regulatory mechanisms are related.
Here, we have functionally defined the minimal human
CAR promoter and have shown that it contains four
orthologously conserved motifs: putative ETS and CRE
elements, and two closely spaced E2 boxes. Particularly
the latter elements caught our attention, since they were
reported to interact with E2 box transcriptional repres-
sors such as ZEB1 [25,33-36] and SIP1 [23,33,35,39] in
the E-cadherin promoter. Furthermore, the genetic con-
text of the E2 boxes in the CAR (Figure 1B) and E-cad-
herin [39] promoters is similar. Indeed, overexpressed
ZEB1 repressed the activity of the -291/-1 CAR promo-
ter, and bound to CAR promoter oligonucleotides and
chromatin. It is of note that Pong et al. suggested that
the functional CAR promoter is located between -585
and -400 [10]. However, since the latter study did not
address the role of the E2 boxes and primarily focused
on CAR upstream sequence mediating positive regula-
tion of promoter activity, it does not contradict our
findings. Indeed, we have shown that the -681/-1 CAR
upstream fragment, containing the proposed -585/-400
promoter, is associated with high promoter activity (Fig-
ure 1A).
Our ZEB1 knockdown experiments provide evidence
that ZEB1 is a physiological repressor of CAR expres-
sion in PANC-1 and MDA-MB-231 cells. However, even
though knockdown of ZEB1 was sufficient to antagonize
the TGF-b-induced down-regulation of CAR and E-cad-
herin (Figure 5A), we did not observe consistent
changes of the ZEB1 protein levels in PANC-1 cells
neither in total nor nuclear fractions as consequence of
the TGF-b stimulation (Figure 5A-C). Therefore, in our
PANC-1 EMT model, TGF-b may activate ZEB1 rather
than up-regulate its expression. Underlying mechanisms
have not been described yet but may include posttran-
slational modification of ZEB1 or physical binding to
TGF-b downstream effectors. For instance, TGF-b may
enhance ZEB1’s repressor activity by up-regulating
expression and/or activity of ZEB1-associated co-
Net:
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Figure 6 ZEB1 as a constitutive repressor of the CAR promoter
in PANC-1 cells. Our data supports a model in which ZEB1
constitutively binds to E2 box 1 (Fig. 4B) in the human CAR
promoter thereby controlling the basal levels of CAR. TGF-b may
further repress the promoter via E2 box 2 and its adjacent Smad-
binding element (SBE) by a mechanism likely involving Snail-Smad3/
4 [37]. Knockdown of ZEB1 increases CAR expression despite the
presence of Snail-Smad3/4. Factors binding to the ETS-CRE region
(Fig. 1C), here speculatively indicated as ETS or CREB, strongly
induce CAR expression ("+++”), while ZEB1 and Snail-Smad3/4
negatively ("-”) regulate the CAR promoter. Net CAR expression
indicates overall promoter activity. See text for details.
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Page 12 of 16repressors such as CtBP-1/-2 and/or BRG1. In support,
TGF-b stimulation increased both ctbp1 and brg1
mRNA levels in NMuMG cells ([53], supplementary
t a b l eI ) ,am u r i n ec e l ll i n ef o rw h i c hw ea n do t h e r s
reported a TGF-b-mediated down-regulation of CAR
[9,37]. However, in contrast to our data obtained with
(human) PANC-1 cells, NMuMG cells responded to
TGF-b stimulation with increased ZEB1 (δEF1) expres-
sion [35]. Nevertheless, BRG1 was shown to physically
associate with ZEB1 to repress the E-cadherin promoter
[54].
Even though ZEB1 is necessary for the TGF-b-induced
inhibition of CAR expression, TGF-b may activate fac-
tors other than co-repressors that physically interact
with ZEB1 to down-regulate CAR. In such a model,
ZEB1 would play a role as a constitutive repressor of
CAR and thereby counteract activating factors such
as those interacting with the ETS and CRE elements
(Figure 1). siRNA-mediated depletion of ZEB1 would
ease repression and consequentially increase CAR levels.
Such a model appears attractive (Figure 6): Snail-
Smad3/4 was shown to repress the mouse CAR promo-
ter by a mechanism that involves interactions with E2
boxes and adjacent Smad-binding elements (SBEs) [37].
Intriguingly, similarly to the mouse CAR promoter, E2
box 2 in the human CAR promoter contains an adjacent
SBE (5’-CAGA-3’) as well (Figure 1B). This may indicate
that the human CAR promoter can also potentially be
inhibited by Snail-Smad3/4 [37]. Therefore, ZEB1 may
regulate the basal CAR levels by mediating a certain
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Figure 7 Up-regulation of cell-surface CAR levels upon ZEB1 knockdown coincides with increased adenoviral infectability. A and B.
Cell-surface CAR levels following ZEB1 knockdown were measured by flow cytometry on PANC-1 cells treated with TGF-b1( A), or on MDA-MB-
231 cells (B). Error bars represent standard deviations (biological duplicates). C and D. Ad-GFP uptake following ZEB1 knockdown was
determined by flow cytometry measuring GFP levels (C), or by real-time PCR for virus copy number (D). Error bars represent standard deviations.
A-D. CAR and GFP signals are expressed as geometric means of the fluorescence signal intensities normalized to the untreated controls (A-C),
virus copy numbers as relative adenovirus fiber levels (D). Abbreviations: UT, untransfected; Ctrl #1, siControl ON-TARGETplus Non-targeting siRNA
#1 (Dharmacon); Ctrl #2, firefly luciferase-targeting siRNA; ZEB1 siRNA #1/#2, ZEB1-targeting siRNAs. Ctrl #2 and ZEB1 siRNA sequences are
provided in Additional file 1 (Table S3). p < 0.001 (***), p < 0.01 (**) (Student’s t-test, 1-tailed, equal variance).
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Page 13 of 16degree of promoter inhibition when bound to E2 box 1.
However, further repression through binding of Snail-
Smad3/4 to E2 box 2 may occur upon stimulation with
TGF-b (Figure 6). The assumption that the mesenchy-
mal factor ZEB1 is bound to the CAR promoter even in
the absence of TGF-b may be regarded as a discrepancy
to the epithelial features of PANC-1 cells (Figure 2, 3
and 5). However, even though these cells undergo TGF-
b-induced EMT, they may not be prototypical epithelial
cells as they express some mesenchymal/stem cell mar-
kers and can be brought into a more typical epithelial
state by inhibiting Cyr61 [55]. Furthermore, even though
functional characterization of the role of Snail-Smad3/4
on the CAR promoter was conducted in mouse cells, in
invasive human ductal breast carcinoma, nuclear expres-
sion of Snail, Smad3 and Smad4 correlated with loss of
CAR expression at the invasive front [37]. This data is
consistent with our model which postulates that Snail-
Smad3/4 may also negatively regulate the human CAR
promoter (Figure 6).
Our work identifies ZEB1 as a negative regulator of
cell-surface CAR expression and adenovirus uptake and
thus as a candidate therapeutic target in treatment stra-
tegies with oncolytic adenoviruses. Responsive tumor
types may include moderately to poorly differentiated
gastrointestinal tumors with low CAR expression [4].
However, whether or not this approach is successful
does not solely depend on how efficiently the virus is
taken up by the respective target cells, but also how
effectively it replicates once taken up. We and others
recently demonstrated that p21
WAF1 acts as a negative
regulator of adenovirus replication [7,11]. For instance,
even though the HDAC inhibitor valproic acid (VPA)
up-regulated CAR, and facilitated adenovirus uptake, it
additionally increased p21
WAF1 levels and reduced virus
replication [7]. Therefore, if such a scenario also applies
to approaches targeting ZEB1, it might be necessary to
engineer a replication-competent adenovirus able to
silence p21 expression to improve replication and cell
killing.
In summary, we have shown that ZEB1 negatively reg-
ulates CAR expression and adenovirus uptake in the
context of TGF-b-mediated EMT, and that inactivation
of ZEB1 may induce some form and degree of MET.
We have demonstrated that knockdown of ZEB1 antag-
onized the TGF-b-mediated EMT process and the
down-regulation of CAR in PANC-1 cells.
Conclusions
Our findings may suggest that carcinoma cells in vivo,
stimulated by stroma-derived TGF-b,m i g h tr e s p o n dt o
ZEB1 inactivation with MET resulting in reduced inva-
siveness and CAR up-regulation, and in improved
adenovirus uptake. The latter effect may translate
into more effective therapies utilizing oncolytic
adenoviruses.
Additional material
Additional file 1: Figure S1, Tables S1-S3, and supplemental
methods. Figure S1 demonstrates effects of TGF-b and overexpressed
ZEB1 on SERPINE 1 (PAI-1) and CXADR (CAR) mRNA expression in PANC-1
cells. Table S1 contains corresponding GenBank (NCBI) and Ensemble
database accession numbers and positions of the translational start ATG
of the orthologous CAR promoter sequences used for the alignment
shown in Figure 1B. Tables S2 and S3 contain oligonucleotide
sequences. Supplemental methods include additional experimental
procedures and in-depth descriptions of methods outlined above.
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